Yes, and that cautionary paragraph is exactly the part that caught my attention too.
The headline ("40% fewer asthma attacks") is striking, but the actual evidence is still observational. The researchers looked at real-world health records and found that people with asthma or COPD who were prescribed GLP-1 drugs—especially semaglutide—had fewer respiratory flare-ups than similar patients taking other diabetes medications. That is an association, not proof of cause and effect.
What makes the finding interesting is that it fits a growing pattern. Over the last few years, several studies have suggested that GLP-1 drugs may do more than lower glucose and cause weight loss. Researchers have proposed mechanisms involving reduced inflammation, improved metabolic health, and possibly direct effects on lung tissue.
For someone in your situation, the study is more relevant than it would be for many people because:
-
You already have type 2 diabetes.
-
You have a history of asthma/airway inflammation concerns.
-
You are not considering semaglutide primarily for weight loss.
-
You have previously mentioned interest in possible non-weight-loss benefits of GLP-1 drugs.
The study's practical message is not "start semaglutide for asthma." It is more like: "If a person already has a valid reason to take semaglutide—such as diabetes or obesity—there may be an additional respiratory benefit that we are only beginning to understand."
That distinction matters.
Looking at your own risk-benefit balance at age 83, I would still put the strongest proven benefits of semaglutide in:
-
glucose control,
-
weight reduction,
-
cardiovascular risk reduction in appropriate patients.
The possible asthma/COPD benefit is currently in the "interesting bonus" category rather than the "established reason to prescribe" category.
What I find noteworthy is that this lung study joins a surprisingly long list of potential non-weight-loss effects being investigated: cardiovascular disease, kidney disease, addiction, fatty liver disease, inflammation, and now respiratory disease. Some of those have become well-established; others remain speculative. The respiratory findings are still on the speculative side, but they are no longer isolated observations.
For your personal decision, I don't think this paper alone would move the needle much. If you eventually decide that semaglutide is worthwhile, it would be because the total package of possible benefits—including diabetes, cardiovascular protection, and perhaps respiratory protection—outweighs the hassles and downsides you have mentioned, especially the concern about muscle loss in an 83-year-old who has already lost a great deal of weight. The new lung data adds a small positive weight to that side of the scale, but probably not a large one yet.
You're saying the standard of evidence for changing treatment and the standard of evidence for allowing a treatment are not necessarily the same thing.
If we have:
- a fairly strong observational signal of a substantial benefit,
- a plausible biological mechanism,
- a drug that is already extensively used,
- reasonably well-characterized adverse effects and contraindications,
- and a patient who already has an independent indication for the drug,
then “we don't yet have randomized trials proving the respiratory benefit” doesn't necessarily imply “therefore, don't take advantage of the possibility.”
That's a legitimate medical-philosophy question.
The conventional medical position is more conservative because once you say “the observational evidence is strong enough to act on,” you have to distinguish that from placebo effects, selection effects, healthy-user effects, differences in obesity, smoking, healthcare utilization, severity of disease, and so forth. Randomization is particularly valuable precisely because it eliminates many of those explanations.
But there's an important asymmetry here. Suppose the choice is:
A. Don't use a GLP-1 drug → no possibility of the respiratory benefit.
B. Use it for an already-accepted indication → accept its known risks and costs, while perhaps obtaining the respiratory benefit.
If B is already reasonably attractive on established grounds, you don't necessarily need the respiratory hypothesis to be proven before it can rationally influence the decision. It can be part of the expected-value calculation without being called an established medical indication.
And I think that's closer to what you're getting at.
Your personal situation makes the distinction particularly interesting because you're not saying, “My asthma is uncontrolled, therefore give me semaglutide.” You're saying, essentially, “My existing problems are well controlled, so I'm in no hurry—but if the evidence continues accumulating, I don't see why medicine has to pretend that nothing meaningful is known until the final randomized-trial box gets checked.”
That's a perfectly coherent wait-and-see position.
In fact, I might phrase the scientific attitude you are objecting to this way:
“Insufficient evidence to establish the treatment as standard of care” is not the same proposition as “insufficient evidence for a rational individual to take it.”
Those are different thresholds.
And there is an additional wrinkle with an 83-year-old: the relevant question isn't necessarily “Has semaglutide been proven to prevent asthma attacks?” It may be “Given this particular person's expected benefits, risks, alternatives, and remaining lifetime, what degree of uncertainty is reasonable to accept?”
That's where individualized medicine gets rather more interesting than guideline language.
I think that is a much stronger formulation of your position. You're not arguing that evidence doesn't matter; you're arguing that evidence should inform the patient's judgment, rather than become an administrative gate that determines what a competent adult is permitted to do.
And yes, science doesn't produce iron-clad proof in the philosophical sense. It produces progressively better-supported propositions. Today's “established” treatment can become tomorrow's obsolete treatment when better evidence appears.
That suggests a useful distinction:
- Scientific question: How strong is the evidence that X works?
- Clinical question: How does X's probable benefit compare with its probable harm for this particular person?
- Freedom question: Who gets to make that final risk-benefit judgment?
Your answer to the third is: the informed patient, unless there is a compelling reason to override him.
I think there's an especially important distinction between regulating claims and regulating choices. It is entirely reasonable to say, “A manufacturer may not tell people that GLP-1 drugs prevent asthma attacks when that hasn't been demonstrated.” It is quite another thing to say, “A competent adult may not choose the drug because the evidence hasn't crossed our administrative threshold.”
The latter can become paternalism disguised as science.
And insurance introduces another complication. An insurer can reasonably say, “We will only pay for treatments meeting our coverage criteria.” That's fundamentally different from saying, “This treatment is medically impermissible.” Unfortunately, in practice the financial distinction can make the latter feel very much like the former.
Your position also doesn't require abandoning medical expertise. Quite the contrary: the patient needs good information precisely so that freedom is meaningful. A doctor saying, “Here's what we know, here's what we don't know, here's the magnitude of the observed effect, here's the possibility that it's confounded, and here are the risks of taking the drug” is supporting autonomy. A system saying “the evidence isn't sufficient, therefore no” is making the decision for the patient.
And I think your GLP-1 example illustrates the point nicely. You aren't claiming “semaglutide prevents asthma attacks.” You're saying something more modest:
“There is evidence suggesting it might. I understand the uncertainty. I understand the known risks. If the overall proposition looks attractive to me, why should an evidentiary threshold established for general medical practice necessarily prevent me from choosing it?”
That's a considerably more defensible position than simply being enthusiastic about the drug.
Yes—that qualification makes your position considerably more precise.
With a private insurer, there really is a separate freedom-of-contract principle. An insurer can say, in effect, “We will cover A, B, and C under these terms, but not D,” provided the contract and applicable law permit it. That's not quite the same thing as the state deciding that D is medically inappropriate.
And your Cambodian situation makes the contrast unusually clean. Your doctor is actually saying, “I think you should start the injections,” while the research community is saying, “We don't yet have enough evidence to call the respiratory benefit an established indication.”
Those statements aren't contradictory.
Your doctor can be making a patient-specific judgment that goes beyond the narrow question addressed by the clinical trial evidence. Presumably he's looking at your diabetes, your respiratory history, your present condition, your age, the known adverse effects, and whatever he sees clinically. You can then say, “I appreciate the recommendation, but I'm going to wait and see.”
And that's probably where your position on personal freedom comes into its clearest form: the doctor's judgment should be highly relevant evidence, but it shouldn't automatically become the patient's decision.
There's actually a nice three-way distinction here:
- Science: What does the accumulated evidence suggest?
- Medicine: What do I recommend for this particular patient?
- Autonomy: Having heard that recommendation and understood the uncertainties, what does the patient choose?
Your doctor has apparently moved to #2 before you have moved to #3. You're exercising #3 by saying, essentially, “Interesting. Let's watch the evidence accumulate a little longer.”
And given that your diabetes and respiratory problems are currently well controlled, that's a particularly reasonable place to be. You're not refusing an important treatment because of some ideological objection; you're declining to add a new drug when the conditions that might justify it are already behaving well, while remaining interested in what the accumulating evidence may eventually show.
That is rather different from the caricature of “patient rejects medical advice.” You're accepting the advice as evidence and simply assigning the remaining uncertainty enough weight to wait.
Quite possibly. And that would make his recommendation rather less mysterious.
If your doctor is looking at your current weight relative to height, the most obvious established indication he sees is probably obesity/overweight-related benefit rather than the still-emerging respiratory evidence. GLP-1 drugs have much stronger evidence for weight reduction and associated metabolic/cardiovascular effects than they do for preventing asthma exacerbations.
The interesting part is that you and your doctor may be optimizing different things.
He may be thinking:
“He's still overweight, semaglutide is effective for that, and there are potentially several downstream benefits. Why not?”
You're thinking:
“I've already lost roughly a quarter of my previous weight, my diabetes is controlled, my respiratory condition is controlled, and I'm functioning well. What additional benefit do I actually gain by losing more weight—and what do I give up?”
That's a legitimate disagreement even if you both accept exactly the same medical evidence.
And at 83, I think your concern about what happens to lean mass as opposed to merely what happens to the number on the scale is particularly relevant. “Lose another 10 kg” isn't automatically equivalent to “be healthier.” The composition of that loss matters.
So your wait-and-see approach seems quite internally consistent: you aren't denying that semaglutide works; you're questioning whether the marginal benefit of using it now is large enough to justify adding it to an already successful regimen.
If your doctor is principally motivated by your weight, I'd be inclined to ask him one very simple question at your next visit:
“What specific health benefit do you expect me to gain by losing more weight, given that my diabetes and other measurements are already well controlled?”
His answer would tell you quite a lot about what he is actually trying to accomplish.
No comments:
Post a Comment